medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 3

<< Back Next >>

Ann Hepatol 2011; 10 (3)

Trans-arterial 90yttrium radioembolization for patients with unresectable tumors originating from the biliary tree

Wijlemans JW, Van EKJ, Lam MGEH, Seinstra BA, Smits MLJ, Zonnenberg BA, Van DBMAAJ

Language: English
References: 25
Page: 349-354
PDF size: 327.91 Kb.


ABSTRACT

Patients with malignant tumors originating from the biliary tree have a poor prognosis, since only a minority of tumors can be resected and most palliative regimens have shown only limited success. We present two patients with unresectable tumors, who were treated with trans-arterial 90yttrium radioembolization: a patient with an infiltrating gallbladder carcinoma and a patient with an extensive intrahepatic cholangiocarcinoma. In both cases the treatment was technically feasible, effective in controlling tumor growth, and without significant side effects. In conclusion, the presented cases demonstrate the potential of 90yttrium radioembolization as a palliative treatment option for malignant tumors of the biliary tree.


REFERENCES

  1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-14.

  2. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-76.

  3. Ortner MA. Photodynamic therapy for cholangiocarcinoma: Overview and new developments. Current Opinion in Gastroenterol 2009; 25: 472-6.

  4. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002; 51(Suppl. 6):VI1-VI9.

  5. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Seminars in Liver Dis 2004; 24: 115-25.

  6. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990- 2009. World J Gastroenterol 2009; 15: 4240-62.

  7. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillmoe KD, Choti MA, et al. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-62.

  8. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg 2008; 196: 252-64.

  9. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: A prospective phase II trial. British J Cancer 2002; 87: 702-4.

  10. Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. European J Cancer 2001; 37: 1833-8.

  11. Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. International J Radiation Oncol, Biol, Physics 2008; 72: 1495-501.

  12. Houry S, Haccart V, Huguier M, Schlienger M. Gallbladder cancer: role of radiation therapy. Hepatogastroenterology 1999; 46: 1578-84.

  13. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Seminars in Liver Dis 2004; 24: 165-75.

  14. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-76.

  15. Bilbao JI, Reiser MF. Liver radioembolization with Y-90 microspheres. Berlin: Heidelberg; 2008.

  16. Buscombe JR. Interventional nuclear medicine in hepatocellular carcinoma and other tumours. Nuclear Med Communications 2002; 23: 837-41.

  17. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: Preliminary results. Cardiovasc and Intervent Radiol 2008; 31: 883-8.

  18. Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience. J Gastrointestinal Surg 2008; 12: 129-37.

  19. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Intervent Radiol 2005; 16: 353-61.

  20. 20 Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, van het Schip AD, et al. Yttrium- 90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis. European Radiol 2009; 19: 951-9.

  21. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 3: Comprehensive literature review and future direction. J Vasc Intervent Radiol 2006; 17: 1571-93.

  22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European J Cancer 2009; 45: 228-47.

  23. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. J Hepatology 2001; 35: 421-30.

  24. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium- 90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17: 484-91.

  25. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study. Cancer 2008; 113: 2119-28.




2020     |     www.medigraphic.com